Carol A. Sherman, MD

Articles

Irinotecan and Gemcitabine in Patients With Solid Tumors: Phase I Trial

Caio Max S. Rocha Lima, MD;Swan-swan Leong, MD;Carol A. Sherman, MD;Joshua A. Perkel, MD;Ahmad R. Safa, MD, PhD;Mark R. Green, MD

May 2nd 2002

Using a day 1 and 8, every-3-week schedule, our purpose was to determine the maximum tolerated dose of irinotecan (CPT-11, Camptosar) that can be administered immediately after gemcitabine (Gemzar) at a dose of 1,000 mg/m² IV. In this phase I trial, the maximum tolerated dose was defined as the dose level immediately below the level in which two of the first three patients in any cohort, or at least two of six patients in any expanded cohort, experienced dose-limiting toxicity. Dose-limiting toxicity pertained only to toxicity during the first cycle of treatment. Escalation of irinotecan was planned in groups of three patients, with three additional patients added at the first indication of dose-limiting toxicity. A total of 19 patients have been enrolled.

Irinotecan/Gemcitabine Combination Chemotherapy in Pancreatic Cancer

Caio Max S. Rocha Lima, MD;Carol A. Sherman, MD;Frank J. Brescia, MD;Chris Y. Brunson, MD;Mark R. Green, MD

March 2nd 2001

Gemcitabine (Gemzar) and irinotecan (CPT-11, Camptosar) are active cytotoxic drugs against pancreatic cancer. Preclinical data evaluating the combination of gemcitabine and irinotecan suggest dose-dependent synergistic

Docetaxel Followed by Gemcitabine and Irinotecan in Solid Tumors

Caio Max S. Rocha Lima, MD;Carol A. Sherman, MD;Frank J. Brescia, MD;Mark R. Green, MD

January 1st 2001

Docetaxel (Taxotere), gemcitabine (Gemzar), and irinotecan (Camptosar, CPT-11) are active single agents in a variety of solid tumors. In combination, synergism may be schedule dependent. Preclinical studies suggested

Irinotecan in the Management of Patients With Pancreatic Cancer

Mark R. Green, MD;Melinda Harper, RN;Ahmad R. Safa, MD, PhD;Carol A. Sherman, MD;Chaudry M. Mushtaq, MD;Hamid Bahadori, MD;Frank J. Brescia, MD;Caio Max S. Rocha Lima, MD

December 3rd 2000

Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan ( Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with

Limited Small-Cell Lung Cancer: A Potentially Curable Disease

Carol A. Sherman, MD;Caio Max S. Rocha Lima, MD;Andrew T. Turrisi III, MD

October 1st 2000

Patients with limited-stage small-cell carcinoma of the lung are treated with combined-modality therapy with the intent to cure. Standard therapy consists of platinum-based combination chemotherapy, thoracic irradiation, and